4d Molecular Therapeutics Stock Today
| FDMT Stock | USD 7.84 0.03 0.38% |
Performance0 of 100
| Odds Of DistressLess than 25
|
4D Molecular is selling for under 7.84 as of the 30th of November 2024; that is 0.38 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 7.53. 4D Molecular has about a 25 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for 4D Molecular Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of December 2020 | Category Healthcare | Classification Health Care |
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. The company was founded in 2013 and is headquartered in Emeryville, California. 4D Molecular operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 46.23 M outstanding shares of which 7.83 M shares are currently shorted by private and institutional investors with about 10.17 trading days to cover. More on 4D Molecular Therapeutics
Moving together with FDMT Stock
Moving against FDMT Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
FDMT Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Executive Chairman | John Milligan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Levels4D Molecular can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand 4D Molecular's financial leverage. It provides some insight into what part of 4D Molecular's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4D Molecular Therapeutics (FDMT) is traded on NASDAQ Exchange in USA. It is located in 5858 Horton Street, EmeryVille, CA, United States, 94608 and employs 147 people. 4D Molecular is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 363.81 M. 4D Molecular Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 46.23 M outstanding shares of which 7.83 M shares are currently shorted by private and institutional investors with about 10.17 trading days to cover.
4D Molecular Therapeutics currently holds about 241.09 M in cash with (75.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.45.
Check 4D Molecular Probability Of Bankruptcy
Ownership AllocationThe majority of 4D Molecular Therapeutics outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to acquire positions in 4D Molecular Therapeutics to benefit from reduced commissions. Hence, outside corporations are subject to a different set of regulations than regular investors in 4D Molecular Therapeutics. Please pay attention to any change in the institutional holdings of 4D Molecular as this could imply that something significant has changed or is about to change at the company.
Check FDMT Ownership Details
FDMT Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Assenagon Asset Management Sa | 2024-09-30 | 1.5 M | |
| Novo A/s | 2024-09-30 | 1.5 M | |
| Redmile Group, Llc | 1.3 M | ||
| Braidwell Lp | 2024-09-30 | 1.2 M | |
| Casdin Capital, Llc | 2024-09-30 | 1.1 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1 M | |
| Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 803.5 K | |
| Eagle Health Investments Lp | 2024-09-30 | 462.9 K | |
| Healthcare Of Ontario Pension Plan Trust Fund | 2024-09-30 | 459 K | |
| Bvf Inc | 2024-09-30 | 7.4 M | |
| Ra Capital Management, Llc | 2024-09-30 | 5.1 M |
4D Molecular Historical Income Statement
FDMT Stock Against Markets
4D Molecular Corporate Management
| FAAAAI FAAP | Senior Pulmonology | Profile | |
| Christopher Simms | Chief Officer | Profile | |
| Uneek Mehra | Chief Officer | Profile | |
| JD Esq | Chief Officer | Profile | |
| Mike Zanoni | VP Relations | Profile | |
| Noriyuki MD | Chief Officer | Profile |
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.